X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Wyeth and its new parent Pfizer are probably wishing they had more to be thankful for this week, after being hit with jury awards totaling $103 million over hormone drugs. But what started out as a tough week for Big Pharma got a little better late Monday, when Manhattan federal District Court Judge John Keenan dismissed the second of three bellwether cases facing Merck over its osteoporosis drug Fosamax just weeks before it was set for trial. Keenan ruled on Monday that the plaintiff in the second test case, a 74-year-old Mississippian named Bessie Flemings, had failed to present admissible evidence of specific causation tying her jaw problems to Fosamax. The case had been set to go to trial in January. We’re neither doctors nor lawyers, but it strikes us that Flemings’ situation is pretty extreme for a test plaintiff. The opinion stated that, along with osteoporosis, Flemings “has a history of serious medical problems” including congestive heart failure, vascular disease and skin cancer. She has smoked cigarettes since age eight, and continues to smoke despite suffering from chronic obstructive pulmonary disease and being dependent on an oxygen tank to breathe. But it wasn’t Flemings’ abominable health that finally scuttled her Fosamax claims. Keenan wrote that neither of the dentists who treated her injury and were offered as experts was able to credibly link Flemings’ jaw damage to her use of Fosamax. One of the doctors had no real opinion at all on a possible link, while the other’s opinion was based only on “subjective belief,” the judge wrote. Merck’s lead lawyer, Venable‘s Paul Stain, was has not available to comment directly, but he issued the following statement through Merck: “We are pleased that the Court agreed with us that Ms. Flemings did not present any reliable evidence supporting her claim that FOSAMAX caused her to suffer ONJ [osteonecrosis of the jaw] … . Unfortunately, Ms. Flemings had medical problems that cause people to develop jaw problems regardless of whether they were taking FOSAMAX.” Merck was also represented by Norman Kleinberg and Theodore Mayer of Hughes Hubbard & Reed in the case. Flemings’ lawyer, Robert Germany of Pittman, Germany, Roberts & Welsh, did not respond to our request for comment. The Fosamax plaintiffs all claim that their use of the drug for osteoporosis resulted in painful damage to bone in their jaws and that Merck failed to adequately warn about possible complications. Nearly 900 Fosamax cases are consolidated before Keenan, who last September declared a mistrial in the first test case. That case is set to be re-tried in the spring. Trial in the third case is scheduled for April 19. Daniel Osborn of Osborn Law, who represents the plaintiff in that case, was not available for comment on Tuesday.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.